fbpx

Ep. 508: Prof. Donald Abrams, UCSF

Professor Donald Abrams, Professor of Clinical Medicine at the University of California San Francisco, discusses the usefulness of cannabis in treating a variety of medical conditions: “Cannabis has been a medicine for 3,000 years and only hasn’t been for 77. So I think we can harken back to some of the prehistoric information that we […]

Rethinking the “Gold Standard” of Placebos

Summary of “The End of Placebos is in Sight” by Matthew Chapman, Wired.co.uk For decades, placebos have been considered the “gold standard” of control arms for clinical trials as a means of measuring the efficacy of new treatments. Doctors and scientists speak of placebo-controlled experiments in such a matter-of-fact way that the standard has come […]

Ep. 502: Paige Figi

Paige Figi returns to discuss with us the progress that has been made in cannabis over the past five years — nowadays, cannabis can be discussed in public without anyone batting an eye. Figi focuses on CBD in particular; she shares her daughter’s excellent progress using CBD as a way to control her epilepsy: “She […]

Ep. 500: Prof. Mauro Maccarone

Professor Mauro Maccarone, Chair of Biochemistry and Molecular Biology at Campus Bio-Medico University of Rome, discusses current cannabis research and the dangers of making product claims that are not backed up by science: “Psychiatric illnesses and, more in general, neurological diseases, are one of the areas, maybe together with cancer and pain, where people need […]

Ep. 497: Dr. Matthew Halpert

Dr. Matthew Halpert, instructor of immunology at Baylor College of Medicine, has spent the past year studying and researching the different ways in which CBD interacts with the body: “It’s become very evident that CBD can, in fact, interact with the body in a variety of ways, and exert several different health benefits. It is […]

Cannabinoid Report: CB1/CB2 Receptors

Cannabinoid Receptor Type 1 and Cannabinoid Receptor Type 2 (more familiarly known as the CB1 and CB2 receptors) are two of the body’s major cannabinoid receptors, which are integral to the endogenous cannabinoid system as a whole. The CB1 receptor was discovered in the 1980s through in-vitro studies and was later cloned in 1990. The […]

Condition Report: Brain Trauma/Injury

OVERVIEW In 2017, the National Academies of Science, Engineering & Medicine released a comprehensive report, “The Health Effects of Cannabis & Cannabinoids”, based on the research that had been done to date. Following that valuable report, we’ve been providing weekly Condition Reports on 2018 research for each of the conditions cited in that report, such as […]

Cannabinoid Report: Virodhamine

Virodhamine (also known as O-arachidonoyl ethanolamine or O-AEA) was discovered in 2002 by Porter et al. Virodhamine is one of the body’s many endocannabinoids and is a combination of arachidonic acid and ethanolamine. These two components are formed by an ester linkage, which is the opposite of anandamide’s amide linkage. The name ‘virodhamine’ is based […]

Condition Report: Glaucoma

OVERVIEW In 2017, the National Academies of Science, Engineering & Medicine released a comprehensive report, “The Health Effects of Cannabis & Cannabinoids”, based on the research that had been done to date. Following that valuable report, we’ve been providing weekly Condition Reports on 2018 research for each of the conditions cited in that report, such as […]

Cannabinoid Report: NADA

N-Arachidonoyl dopamine (NADA) is an endogenous cannabinoid that acts as a potent agonist to the body’s CB1 and TRPV1 receptors. NADA was one of the later discovered endocannabinoids, along with 2-AGE and virhodamine. NADA was first proposed as an endocannabinoid in 2000 by T. Bisogno, D. Melck, Bobrov MYu, N. M. Gretskaya, V. V. Bezuglov, […]